SCHEMBL5019059

SCHEMBL5019059

COC(=O)[C@@H](C)Cc1ccc(N)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CXCR1 P25024 1/20 0.44
CXCR2 P25025 1/20 0.44
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
THRB P10828 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ITGB1 P05556 1/20 0.42
ITGA5 P08648 1/20 0.42
SCN1A P35498 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN3A Q9NY46 1/20 0.42
PTPRB P23467 1/20 0.42
PPID Q08752 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22338892 1.00 ESR1 (0.46) ESR1ESR2NPC1RAB9ACXCR1
SCHEMBL19647373 1.00 ESR1 (0.46) ESR1ESR2NPC1RAB9ACXCR1
SCHEMBL15865986 0.85 ESR1 (0.41) ESR1ESR2NPC1RAB9ACXCR1
SCHEMBL2432711 0.84 LMNA (0.51) NPC1RAB9AALDH1A1HSD17B10CYP2C9
SCHEMBL6575139 0.84 ATM (0.50) ESR1ESR2NPC1RAB9ACXCR1
SCHEMBL13534766 0.84 ESR1 (0.47) ESR1ESR2NPC1RAB9ACXCR1
SCHEMBL3992599 0.84 PTPRB (0.58) ESR1ESR2NPC1RAB9ACXCR1
SCHEMBL14564293 0.84 ATM (0.50) ESR1ESR2NPC1RAB9ACXCR1
SCHEMBL5546946 0.84 ESR1 (0.65) ESR1ESR2NPC1RAB9AKMT2A
SCHEMBL14590363 0.84 ATM (0.50) ESR1ESR2NPC1RAB9ACXCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264566-A1 ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-09-15 US disclosed
US-8178490-B2 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2012-05-15 US disclosed
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCB1, SLC47A1 ESR1 4291/4885ESR2 3906/4885NPC1 124/4885
US-20160264566-A1 ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE ITGB1, ITGA1, ITGAV ESR1 3776/4885ESR2 1331/4885NPC1 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.